lq bingo 777 The increase is an addition to the $64 million awarded to X-Bow in 2023 to expand production capacity of the solid rocket motor industrial base. LULING, Texas , Dec. 20, 2024 /PRNewswire/ -- X-Bow Systems Inc. (X-Bow), a leading non-traditional producer of advanced solid rocket motors (SRMs) and defense technologies, today announced the expansion of its contract to provide large solid rocket motors (SRM) to the U.S. Navy and the U.S. Army. This increase reinforces X-Bow as a new supplier of SRMs and strengthens the Defense Department supply chain in a critical period for the United States . Following the increase, X-Bow hosted Ms. Adele Ratcliff , Director of the DoD's Innovation Capability and Modernization (ICAM) Office, at our expanding Texas campus on December 3, 2024 . Ms. Ratcliff leads the Industrial Base Analysis and Sustainment (IBAS) Program, crucial for fortifying the U.S. defense industry and fostering emerging sectors like advanced manufacturing to ensure rapid response to national security needs. Ms. Ratcliff stated, "It is a national imperative that DoD seek new and rapid alternative sources of solid rocket motor production that provide the Department's decisions makers options that not only meet DoD's operational needs but bring capabilities and capacity to bear that grow the defense industrial base (DIB). X-Bow is a critical partner in the DIB ecosystem that aims to provide technical overmatch in the Hypersonics domain." "This contract expansion underscores the critical role X-Bow is playing in modernizing the U.S. defense industrial base," said Max Vozoff , CTO, X-Bow Systems. "Our innovative manufacturing techniques and focus on advanced materials will enable us to deliver high-performance solid rocket motors more efficiently and cost-effectively, strengthening our national security posture." Ms. Ratcliff witnessed X-Bow's new methods for manufacturing SRMs and energetics that will lead to a significant increase in SRM production capacity and decrease in cost for production of SRMs. X-Bow is nearing completion of its Texas campus which, when finished will be the second-largest solid rocket motor production facility in the United States . This facility will significantly enhance our nation's defense readiness. Ms. Ratcliff's visit highlighted the vital role X-Bow plays in strengthening the U.S. Defense Industrial Base through our advanced manufacturing approach to solid rocket motor technology. About X-Bow Systems X-Bow Systems is disrupting the aerospace industry with innovative and cost-effective advanced manufactured energetics for the solid rocket motor and launch vehicle market. X-Bow is also designing and building a suite of modular solid rocket motors and small launch vehicles for both orbital and suborbital launch services. X-Bow is led by CEO Jason Hundley , Chairman Mark Kaufman , CTO Max Vozoff , CRO Maureen Gannon, General Counsel John Leary , COO Mike Bender and a growing team of seasoned industry veterans and new space entrepreneurs. X-Bow is a dual-use technology company with investment from Crosslink Capital, Razor's Edge Ventures, Balerion Space Ventures, Boeing, and Lockheed Martin Ventures. Headquartered in Albuquerque, New Mexico , X-Bow has additional presence in California , Alabama , Colorado , Texas , Utah , Maryland and Washington, DC . For more information visit www.xbowsystems.com . About DoD's Innovation Capability and Modernization (ICAM) Office: The Innovation Capability and Modernization (ICAM) Office manages and executes the DoD's Industrial Base Analysis and Sustainment (IBAS) Program Element, which aims to improve the readiness and competitiveness of the U.S. industrial base by investing in, and establishing high priority domestic capabilities for new supply chains needed for national security and mitigating exposure to global supply chain risks. The appearance of U.S. Department of Defense visual information does not imply or constitute DoD endorsement. View original content to download multimedia: https://www.prnewswire.com/news-releases/x-bow-to-receive-additional-funding-for-expansion-of-dod-contract-for-hypersonic-solid-rocket-motor-development-302337560.html SOURCE X-Bow Systems

University of Kashmir’s NIRF Rankings Reveal Deeper Institutional ChallengesThe South Carolina women's basketball team has been defeated for the first time since March 31, 2023. The No. 1 Gamecocks fell Sunday in Los Angeles as Lauren Betts posted a double-double effort to lead No. 5 UCLA to a 77-62 triumph. The Gamecocks (5-1) suffered their first defeat after 43 consecutive victories, dating back to the loss to Iowa 77-73 in the NCAA Tournament semifinals. South Carolina defeated Iowa last season for the national championship. Betts finished with 11 points, a game-high 14 rebounds, four assists and four blocks to power the Bruins (5-0) to a historic victory. UCLA also got 15 points from Londynn Jones on 5-of-5 shooting from 3-point range, 13 points from Elina Aarnisalo and 11 each from Kiki Rice and Gabriela Jacquez. It's the first time UCLA has beaten South Carolina since 1981. The Bruins lost twice to the Gamecocks in the 2022-23 season, including in the Sweet 16 of the NCAA Tournament. Te-Hina Paopao had 18 points for South Carolina on 4-of-4 3-point shooting, while Tessa Johnson had 14 points. UCLA won the rebounding battle 41-34, marking the second time this season the Gamecocks have been outrebounded. South Carolina also got outscored in the paint 26-18. It's rare that a Dawn Staley-coached team -- units that typically revolve around dominant centers from A'ja Wilson to Aaliyah Boston to Kamilla Cardoso -- gets beat in the paint and on the glass, but with 6-foot-7 Betts, UCLA had the recipe to outmuscle the Gamecocks in those areas of the game. South Carolina never led after UCLA began the game with an 18-5 run, capped off by back-to-back 3-pointers from Jones. The Gamecocks cut the deficit to nine points in the second quarter, but the Bruins responded with a 17-5 run and entered halftime ahead by 21 points. Aarnisalo scored seven points during that run. From there, the Gamecocks never got within single digits of the lead in the second half. It's the first time in 21 tries that UCLA has beaten an AP-ranked No. 1 team. And it's the first time South Carolina lost a true road game since 2021, a streak of 33 games. The schedule doesn't get any easier for South Carolina. While UCLA faces UT Martin next on Friday, the Gamecocks play No. 8 Iowa State on Thursday. --Field Level Media

For some FSA dollars, it's use it or lose it at year's endThe dynamics of the germ cell tumors market are anticipated to change in the coming years owing to the approval of specialized therapies for GCT and anticipated greater patients getting access to treatment across the world. Some key players such as Exelixis (Cabozantinib), Daiichi Sankyo (DS-9606), and HiFiBiO Therapeutics (HFB200301) are investigating their candidates to treat GCT in the 7MM. LAS VEGAS , Dec. 18, 2024 /PRNewswire/ -- DelveInsight's Germ Cell Tumors Market Insights report includes a comprehensive understanding of current treatment practices, germ cell tumors emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan]. Key Takeaways from the Germ Cell Tumors Market Report According to DelveInsight's analysis, the market size for germ cell tumors in the 7MM is expected to reach ~ USD 630 million by 2034. Cabozantinib is expected to garner the largest market share of USD 129 million in the US by 2034, followed closely by DS-9606a , with a market share of USD 63 million . The incidence of GCT is around 26,000 cases in the 7MM in 2023. Leading germ cell tumors companies such as AstraZeneca, Exelixis, Pfizer, Xencor, Inc., Daiichi Sankyo, HiFiBiO Therapeutics, and others are developing novel germ cell tumors drugs that can be available in the germ cell tumors market in the coming years. The promising germ cell tumor therapies in the pipeline include Cabozantinib, Talazoparib, XmAb541, DS-9606a, and HFB200301, among others. Discover which therapies are expected to grab the major Germ Cell Tumors market share @ Germ Cell Tumors Market Report Germ Cell Tumors Overview Germ cell tumors are a rare type of growth that originates from germ cells, the cells responsible for developing into sperm in males and eggs in females. These tumors can be benign or malignant and often develop in the gonads, but they can also arise in other areas of the body, such as the abdomen, chest, or brain. The exact cause of germ cell tumors is not always clear, but genetic and environmental factors may play a role. Some known risk factors include abnormal development of the gonads, family history of similar conditions, and certain inherited syndromes. Germ cell tumor symptoms depend on the tumor's location and size. Common signs include swelling or a mass in the affected area, abdominal or chest pain, difficulty breathing (in cases of tumors in the chest), or hormonal changes. In some cases, the tumors may cause symptoms such as fatigue or unexplained weight loss. Germ cell tumor diagnosis typically involves a combination of imaging studies, blood tests to measure tumor markers like alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (β-hCG), and biopsy or surgical removal of the tumor to determine its nature. Early detection and treatment are crucial for improving outcomes, with therapies including surgery, chemotherapy, radiation, or a combination of these approaches. Germ Cell Tumors Epidemiology Segmentation The germ cell tumors epidemiology section provides insights into the historical and current germ cell tumors patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The germ cell tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of GCT Type-specific Incident Cases of GCT Sub-type specific Cases of Gonadal GCT Age-specific Cases of GCT Gender-specific Incident Cases of GCTs Total Incident Cases of GCTs by Stage Total Treatable Cases of GCT Line-wise Treatable Cases of GCT Germ Cell Tumors Treatment Market The treatment approach for germ cell tumors depends on the tumor type, whether ovarian or testicular. Surgery, followed by chemotherapy and sometimes radiation therapy, forms the cornerstone of GCT management. For recurrent testicular cancer, a chemotherapy combination of ifosfamide (Ifex), paclitaxel (Taxol), and cisplatin (Platinol) has proven highly effective. Notably, testicular cancers were among the first cancers successfully treated with radiation or chemotherapy. Over 80% of patients with metastatic germ cell tumors achieve a cure with cisplatin-based chemotherapy, typically the bleomycin, etoposide, and cisplatin (BEP) regimen, combined with surgery for residual disease. However, only about 25% of patients who relapse attain long-term survival after second-line cisplatin-based therapy, often using the vinblastine, ifosfamide, and cisplatin (VeIP) regimen. BEP remains the standard first-line chemotherapy for GCTs, effective in both seminomas and nonseminomas. This regimen capitalizes on cisplatin's DNA-damaging properties, etoposide's inhibition of DNA synthesis, and bleomycin's ability to induce DNA strand breaks, resulting in high cure rates. Treatment typically involves 3 to 4 cycles, tailored to disease stage and risk factors. Advancements in surgical techniques, rising incidence rates, and improved post-surgical outcomes have increased the demand for surgical interventions, driving growth in the broader GCT treatment market. To know more about germ cell tumor treatment guidelines, visit @ Germ Cell Tumors Management Germ Cell Tumors Pipeline Therapies and Key Companies Durvalumab + Tremelimumab: AstraZeneca Cabozantinib: Exelixis Talazoparib: Pfizer XmAb541: Xencor, Inc. DS-9606a: Daiichi Sankyo HFB200301: HiFiBiO Therapeutics Discover more about germ cell tumor drugs in development @ Germ Cell Tumors Clinical Trials Germ Cell Tumors Market Dynamics The germ cell tumors market dynamics are expected to change in the coming years. Platinum-based chemotherapy , such as the BEP regimen, is highly effective in treating both early and advanced-stage germ cell tumors, while surgical interventions like orchiectomy or oophorectomy also contribute significantly to successful outcomes. Biomarkers such as AFP, hCG, and LDH play a crucial role in diagnosis, staging, and monitoring treatment response, facilitating enhanced clinical decision-making and personalized care. Ongoing research into the genetic and molecular drivers of GCTs holds promise for developing highly effective, less toxic therapies, particularly for refractory or relapsed cases. Furthermore, identifying and validating new biomarkers could improve diagnosis, risk stratification, and relapse detection , advancing personalized treatment approaches for patients, including those with non-secretory tumors. Furthermore, potential therapies are being investigated for the treatment of germ cell tumors, and it is safe to predict that the treatment space will significantly impact the germ cell tumors market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the germ cell tumors market in the 7MM. However several factors may impede the growth of the germ cell tumors market. Platinum-based chemotherapy is highly effective but is associated with significant acute toxicities , such as nephrotoxicity and ototoxicity, as well as long-term effects like secondary malignancies, which can severely impact the quality of life, particularly for young survivors. Additionally, approximately 10–15% of patients develop resistance to first-line therapies , leaving them with few effective options, as salvage treatments are often toxic and have limited success rates. The emergence of resistance to platinum-based chemotherapy, especially in advanced or metastatic cases, poses a significant challenge, threatening the high cure rates associated with GCTs . Furthermore, the cost of advanced therapies , including novel drugs and long-term survivorship care, places a substantial financial burden on patients and healthcare systems, potentially limiting access to effective treatments. Moreover, germ cell tumor treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, germ cell tumors market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact germ cell tumors market growth. Scope of the Germ Cell Tumors Market Report Therapeutic Assessment: Germ Cell Tumors current marketed and emerging therapies Germ Cell Tumors Market Dynamics: Key Market Forecast Assumptions of Emerging Germ Cell Tumors Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Germ Cell Tumors Market Access and Reimbursement Download the report to understand which factors are driving germ cell tumors market trends @ Germ Cell Tumors Market Trends Table of Contents Related Reports Non-small Cell Lung Cancer Market Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including EMD Serono, Merck, Cellular Biomedicine Group, Inc., Celgene, CellSight Technologies, Inc., BeyondSpring Pharmaceuticals Inc., J Ints Bio, Forward Pharmaceuticals Co., Ltd., AstraZeneca, Bristol-Myers Squibb, Teligene US, Rain Oncology Inc, ReHeva Biosciences, Inc., Amgen, Novartis, RedCloud Bio, Parexel, Vitrac Therapeutics, LLC, Mythic Therapeutics, Instil Bio, Mirati Therapeutics Inc., Daiichi Sankyo, Inc., AstraZeneca, Precision Biologics, Inc, Promontory Therapeutics Inc., Palobiofarma SL, Regeneron Pharmaceuticals, Revolution Medicines, Inc., Cullinan Oncology, LLC, Iovance Biotherapeutics, Inc., Innate Pharma , among others. Non-small Cell Lung Cancer Pipeline Non-small Cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NSCLC companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang , Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre , Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others. Small Cell Lung Cancer Market Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm , Carrick Therapeutics, among others. Small-cell Lung Cancer Pipeline Small-cell Lung Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small-cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm , Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee's Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLPBest Beginner-Friendly Stocks to Buy Now in Canada

Charles Barkley crushes Lakers’ ‘awful’ handling of Bronny James - New York Post'Most corrupt president': Outrage mounts over Trump's latest move in government takeover

More funds to support steel workers and businessesThe Government has announced it is doubling funds to support workers and businesses affected by job losses at a giant Tata steel plant. Ministers said an extra £15 million will be made available for supply chain businesses and workers affected by changes at Tata’s Port Talbot site in south Wales. Welsh Secretary Jo Stevens said the move means a fund to support businesses across Wales heavily reliant on Tata steel will be increased to £30 million. She also announced that more businesses will be able to apply for the funds, and the value of individual grants is increasing to up to £250,000 for businesses to invest in equipment, property, technology. The Government said there has been “significant demand” on the existing funding, with almost 40 businesses employing 2,000 people having begun the application process. Grants worth millions of pounds are expected to be released in the new year. The increase in funding is in anticipation of more people leaving Tata in early 2025 through the company’s voluntary redundancy scheme. Ms Stevens said: “This Government is acting decisively to support workers and businesses in Port Talbot. “We are doubling the funding available to businesses and workers and widening access to grants to ensure we support as many people as possible. “In just four months we have announced more than £40 million in investment. We said we would back workers and businesses affected by the transition at Port Talbot and we are doing exactly that. “While this remains a very difficult time for Tata workers, their families and the community, we are determined to support workers and businesses in our Welsh steel industry, whatever happens.”

More funds to support steel workers and businesses

President Joe Biden's administration said Friday that it has cemented deals for billions in funding to South Korean semiconductor giant Samsung Electronics and Texas Instruments to boost their chipmaking facilities in the United States. US officials have been working to solidify Biden's legacy to bolster domestic semiconductor manufacturing ahead of President-elect Donald Trump's White House return -- and these agreements are among the latest efforts to do so. The United States has been trying to reduce its dependence on other countries for semiconductors, while also seeking to maintain its scientific and technological edge as competition with China intensifies. Samsung's award of up to $4.7 billion in direct funding goes towards its effort to grow its Texas presence into a full-fledged operation for developing and producing leading-edge chips, said the US Commerce Department. The funding will supplement the company's investment of more than $37 billion in the coming years, the department added. Samsung's expansion will help "ensure we have a steady, domestic supply of the most advanced semiconductors that are essential to AI and national security, while also creating tens of thousands of good-paying jobs," Commerce Secretary Gina Raimondo said in a statement. National Economic Advisor Lael Brainard added that Samsung is "the only semiconductor company that is a leader in both advanced memory and advanced logic chips." In a separate notice, the Commerce Department said it also had finalized an award of up to $1.6 billion for Texas Instruments, supporting its efforts to build new facilities. Raimondo noted that shortages of current-generation semiconductors were a problem during the supply chain disruptions sparked by the Covid-19 pandemic, adding that TI now plans to grow its US capacity in making these devices. The Biden administration has unveiled billions in grants through the CHIPS and Science Act, a major law passed during the veteran Democrat's term aimed at strengthening the US semiconductor industry. Officials have managed to get many deals across the finish line before Trump returns to the Oval Office, awarding the vast majority of more than $36 billion in proposed incentives that have been allocated. The finalized deals mean funds can be disbursed as companies hit project milestones. bys/sstYankees’ Juan Soto Predicted to Leave for Biggest Rival - Heavy.comMore funds to support steel workers and businesses

Horse racing tips: Templegate’s NAP has been a revelation in handicaps and devours track and trip

Lumo Therapy Launches High-Energy Light Therapy Moodlight 12-20-2024 12:48 AM CET | Sports Press release from: ABNewswire Lumo Therapy, a groundbreaking innovation in personal wellness, is now available to customers seeking effective, non-invasive light therapy solutions. Designed with advanced technology, Lumo Therapy harnesses the proven benefits of light therapy to help alleviate seasonal affective disorder (SAD), enhance mood, and boost energy levels. This cutting-edge device is currently being offered with an exclusive 70% discount, making it an accessible solution for individuals committed to improving their mental and emotional well-being. Lumo Therapy is engineered for individuals looking to harness the natural power of light to combat fatigue, stress, and seasonal blues [ https://rebrand.ly/lumotherapy ]. Its sleek, portable design ensures users can enjoy its benefits at home, in the office, or on the go. With customizable settings and therapeutic-grade light wavelengths, this device is at the forefront of health innovation. Light therapy has been a trusted method in addressing mood disorders and energy imbalances for decades. Studies show that exposure to specific wavelengths of light can positively affect the body's circadian rhythm, boost serotonin levels, and decrease melatonin production. Lumo Therapy amplifies these benefits by using state-of-the-art LED technology to deliver consistent, targeted light exposure, helping users feel rejuvenated and balanced throughout their day. Seasonal depression and energy dips affect millions globally, especially during the colder months. Reduced sunlight during fall and winter can disrupt the body's internal clock, leading to fatigue, mood swings, and diminished productivity. Lumo Therapy offers a natural, effective solution to these challenges, providing users with the boost they need to maintain a positive outlook and energy year-round. This exclusive 70% discount comes at a critical time, ensuring the benefits of Lumo Therapy are accessible to everyone [ https://rebrand.ly/lumotherapy ]. Whether it's for professional demands, personal obligations, or general health improvement, the device equips individuals to perform their best no matter the season. Benefits of Lumo Therapy * Alleviates Seasonal Affective Disorder (SAD): Fight the "winter blues" and feel energized all year. * Boosts Energy and Mood: Improve your mental clarity and emotional state without relying on medication. * Portable and Easy-to-Use: Lightweight and compact for use at home, work, or while traveling. * Customizable Settings: Adjust intensity and duration to fit your specific needs and preferences. * Backed by Science: Trusted by health professionals and supported by decades of research in light therapy. Early users of Lumo Therapy have shared overwhelmingly positive feedback. "Lumo Therapy has truly been a game-changer for me," says Nina Williams, a verified user. "After just a few sessions, I felt more energetic and focused. I can't imagine starting my day without it!" The exclusive 70% discount can be redeemed through Lumo Therapy's official website. To claim this offer and transform your well-being today. Supplies are limited, so don't miss this opportunity to experience the benefits of light therapy at a fraction of the cost. Lumo Therapy is a leading innovator in wellness technology, committed to creating products that enhance quality of life through science-backed solutions [ https://rebrand.ly/lumotherapy ]. With a focus on accessibility, effectiveness, and user experience, Lumo Therapy is transforming the landscape of personal health and well-being. Media Contact Company Name: News Zone Contact Person: Media Relations Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=lumo-therapy-launches-highenergy-light-therapy-moodlight ] Country: United States Website: https://rebrand.ly/lumotherapy This release was published on openPR.Oregon’s college-going rates tick up slightly